BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia

Fourth Quarter and Full Year 2020 Financial Results Conference Call

Mar 11, 2021 • 8:30am EDT

BXCL501 Focused Virtual KOL Day

Feb 19, 2021 • 11:00am - 2:00pm EDT